Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Gross Profit (2022 - 2025)

BioXcel Therapeutics has reported Gross Profit over the past 4 years, most recently at $224000.0 for Q4 2025.

  • Quarterly results put Gross Profit at $224000.0 for Q4 2025, up 148.07% from a year ago — trailing twelve months through Dec 2025 was $478000.0 (up 291.8% YoY), and the annual figure for FY2025 was $478000.0, up 288.62%.
  • Gross Profit for Q4 2025 was $224000.0 at BioXcel Therapeutics, up from $87000.0 in the prior quarter.
  • Over the last five years, Gross Profit for BTAI hit a ceiling of $1.0 million in Q2 2024 and a floor of -$956000.0 in Q3 2024.
  • Median Gross Profit over the past 4 years was $140000.0 (2022), compared with a mean of $76714.3.
  • Peak annual rise in Gross Profit hit 154.82% in 2024, while the deepest fall reached 459.06% in 2024.
  • BioXcel Therapeutics' Gross Profit stood at $229000.0 in 2022, then crashed by 247.6% to -$338000.0 in 2023, then plummeted by 37.87% to -$466000.0 in 2024, then surged by 148.07% to $224000.0 in 2025.
  • The last three reported values for Gross Profit were $224000.0 (Q4 2025), $87000.0 (Q3 2025), and $13000.0 (Q2 2025) per Business Quant data.